This trial is active, not recruiting.

Conditions acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative disorders, chronic myeloid leukemia
Sponsor Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Start date July 2007
End date June 2011
Trial size 143 participants
Trial identifier NCT01683123, get-buf-2010-02


Analyze the results of conditioning with once-daily dose intravenous busulfan and fludarabine in patients undergoing HLA identical sibling Allogeneic HSCT for myeloid malignancies.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective retrospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Acute Myeloid Leukemia - Myelodysplastic Syndrome - Myeloproliferative Disorders - Chronic Myeloid Leukemia Exclusion Criteria: - Performance status ECOG>2 - Cardiomyopathy (LVEF <39%) - Pulmonary dysfunction (DLCO<39%) - Hepatic dysfunction Grade >1 - Renal dysfunction Grade >1 (Creatinine > 1.6 mg/dl) - HIV infection - Other active neoplasm

Additional Information

Official title Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.
Principal investigator Javier De la Serna, MD
Description In this study the investigators evaluate a conditioning regimen consisting in Fludarabine 40 mg/m2 once daily i.v in 60 min. on days -6 to -3 (total dose 160 mg/m2), followed by Busulfan 3,2 mg/kg once daily i.v. in 180 min. in the same days (total dose 12,8 mg/kg). No busulfan pharmacokinetic monitoring is performed. Graft versus host disease prophylaxis consists in the combination of cyclosporine and methotrexate. Graft products obtained from bone marrow or peripheral blood of HLA identical sibling donors are not manipulated in their cellular content before transplantation. Blood products were leukocyte depleted and irradiated before transfusion. Supportive care, including seizure prophylaxis, isolation measures, antiemetics, antimicrobial agents and growth factors use are followed according to standard procedures. The main objectives are to record data regarding engraftment, regimen related toxicity and outcome in different patient populations according to age, disease type, disease status at HSCT and comorbidities.
Trial information was received from ClinicalTrials.gov and was last updated in September 2012.
Information provided to ClinicalTrials.gov by Grupo Espanol de trasplantes hematopoyeticos y terapia celular.